Affordable Access

The European Organization for Research and Treatment of Cancer experience with teniposide: Preliminary results of a randomized study in non-small cell lung cancer

Authors
Journal
Seminars in Oncology
0093-7754
Publisher
Elsevier - WB Saunders
Publication Date
Disciplines
  • Medicine

Abstract

Abstract Chemotherapy for non-small cell lung cancer (NSCLC) is unsatisfactory, and the search for new active drugs has been relatively unsuccessful. Most polychemotherapy regimens in NSCLC include cisplatin with a vinca alkaloid or etoposide. Among the new agents tested in recent years, teniposide produced a 17% response rate in 42 evaluable patients, with a 21% response rate in untreated patients. The Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer has started a randomized trial comparing two different schedules of teniposide administration with and without cisplatin. This paper reports the preliminary findings for the initial 80 patients in this randomized study.

There are no comments yet on this publication. Be the first to share your thoughts.